Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 302

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 302
---
621 shares authorized, issued and outstanding as of June 30, 2025 and December 31, 2024, respectively— 110,791 Series C convertible preferred stock, $0.001 par value, no shares and 18,628,970 shares authorized, issued and outstanding as of June 30, 2025 and December 31, 2024, respectively— 181,328 Total convertible preferred stock— 330,368 Stockholders’ equity (deficit):Preferred stock, $0.001 par value, 10,000,000 and no shares authorized as of June 30, 2025 and December 31, 2024, respectively; no shares issued or outstanding as of June 30, 2025 and December 31, 2024— — Common stock, $0.001 par value, 500,000,000 and 55,200,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 44,132,338 and 4,798,721 shares issued, 44,132,338 and 4,722,763 shares outstanding as of June 30, 2025 and December 31, 2024, respectively44 5 Additional paid-in capital551,838 17,000 Accumulated other comprehensive income183 368 Accumulated deficit(215,636)(181,086)Total stockholders’ equity (deficit)336,429 (163,713)Total liabilities, convertible preferred stock and stockholders’ equity (deficit)$352,048 $185,752 

The accompanying notes are an integral part of these condensed consolidated financial statements. 

F-2

Table of Contents

SIONNA THERAPEUTICS, INC. 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 

(in thousands, except share and per share data) 

(Unaudited)

Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Operating expenses:Research and development$15,383 $8,233 $29,051 $18,453 General and administrative6,523 3,059 12,514 5,986 Total operating expenses21,906 11,292 41,565 24,439 Loss from operations(21,906)(11,292)(41,